| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2082863 | Drug Discovery Today: Therapeutic Strategies | 2012 | 5 Pages |
Abstract
The treatment of LUTS (Lower Urinary Tract Symptoms) has evolved from primarily surgical to medical management. Medical management itself has evolved from single agent to combination therapy. Treatments for BPH (Benign Prostatic Hyperplasia) are aimed at improving subjective symptoms and quality of life. α-Blockers and 5-α reductase inhibitors are the two main categories for treatment. In addition, both antimuscarinic agents and phosphodiesterase inhibitors have been shown to be effective in the management of LUTS. We discuss the current role of these agents in combination for the management of LUTS associated with BPH.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Bilal Chughtai, Richard Lee, Alexis E. Te, Steven Kaplan,